TY - JOUR
T1 - Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease
AU - Gaig, Carles
AU - Compta, Yaroslau
AU - Heidbreder, Anna
AU - Marti, Maria J
AU - Titulaer, Maarten J
AU - Crijnen, Yvette
AU - Högl, Birgit
AU - Lewerenz, Jan
AU - Erro, María Elena
AU - Garcia-Monco, Juan Carlos
AU - Nigro, Pasquale
AU - Tambasco, Nicola
AU - Patalong-Ogiewa, Maja
AU - Erdler, Marcus
AU - Macher, Stefan
AU - Berger-Sieczkowski, Evelyn
AU - Höftberger, Romana
AU - Geis, Christian
AU - Hutterer, Markus
AU - Milán-Tomás, Angela
AU - Martin-Bastida, Antonio
AU - Manzanares, Lydia Lopez
AU - Quintas, Sonia
AU - Höglinger, Günter U
AU - Möhn, Nora
AU - Schoeberl, Florian
AU - Thaler, Franziska S
AU - Asioli, Gian Maria
AU - Provini, Federica
AU - Plazzi, Giuseppe
AU - Berganzo, Koldo
AU - Blaabjerg, Morten
AU - Brüggemann, Norbert
AU - Farias, Tarsis
AU - Ng, Chen Fei
AU - Giordana, Caroline
AU - Herrero-San Martín, Alejandro
AU - Huebra, Lucio
AU - Kotschet, Katya
AU - Liendl, Herburg
AU - Montojo, Teresa
AU - Morata, Carlos
AU - Perez, Jesus Perez
AU - Puertas, Inmaculada
AU - Seifert-Held, Thomas
AU - Seitz, Caspar
AU - Simabukuro, Mateus Mistieri
AU - Tellez, Nieves
AU - Villacieros-Álvarez, Javier
AU - Willekens, Barbara
AU - Sabater, Lidia
AU - Iranzo, Alex
AU - Cano, Joan Santamaria
AU - Dalmau, Josep
AU - Graus, Francesc
N1 - © 2021 American Academy of Neurology.
PY - 2021
Y1 - 2021
N2 - OBJECTIVE: Anti-IgLON5 disease is a recently described neurological disease that shares features of autoimmunity and neurodegeneration. Abnormal movements appear to be frequent and important but have not been characterized and are under-reported. Here we describe the frequency and types of movement disorders in a series of consecutive patients with this disease.METHODS: In this retrospective, observational study, the presence and phenomenology of movement disorders were assessed with a standardized clinical questionnaire. Available videos were centrally reviewed by three experts in movement disorders.RESULTS: Seventy two patients were included. In 41 (57%) the main reason for initial consultation was difficulty walking along with one or several concurrent movement disorders. At the time of anti-IgLON5 diagnosis, 63 (87%) patients had at least one movement disorder with a median of three per patient. The most frequent abnormal movements were gait and balance disturbances (52 patients, 72%), chorea (24, 33%), bradykinesia (20, 28%), dystonia (19, 26%), abnormal body postures or rigidity (18, 25%), and tremor (15, 21%). Other hyperkinetic movements (myoclonus, akathisia, myorhythmia, myokymia, or abdominal dyskinesias) occurred in 26 (36%) patients. The craniofacial region was one of the most frequently affected by multiple concurrent movement disorders (23 patients, 32%) including dystonia (13), myorhythmia (6), chorea (4) or myokymia (4). Considering any body region, the most frequent combination of multiple movement disorders consisted of gait instability or ataxia associated with craniofacial dyskinesias or generalized chorea observed in 31(43%) of patients. In addition to abnormal movements, 87% of patients had sleep alterations, 74% bulbar dysfunction, and 53% cognitive impairment. Fifty-five (76%) patients were treated with immunotherapy, resulting in important and sustained improvement of the movement disorders in only seven (13%) cases.CONCLUSIONS: Movement disorders are a frequent and leading cause of initial neurological consultation in patients with anti-IgLON5 disease. Although multiple types of abnormal movements can occur, the most prevalent are disorders of gait, generalized chorea, and dystonia and other dyskinesias that frequently affect craniofacial muscles. Overall, anti-IgLON5 disease should be considered in patients with multiple movement disorders, particularly if they occur in association with sleep alterations, bulbar dysfunction, or cognitive impairment.
AB - OBJECTIVE: Anti-IgLON5 disease is a recently described neurological disease that shares features of autoimmunity and neurodegeneration. Abnormal movements appear to be frequent and important but have not been characterized and are under-reported. Here we describe the frequency and types of movement disorders in a series of consecutive patients with this disease.METHODS: In this retrospective, observational study, the presence and phenomenology of movement disorders were assessed with a standardized clinical questionnaire. Available videos were centrally reviewed by three experts in movement disorders.RESULTS: Seventy two patients were included. In 41 (57%) the main reason for initial consultation was difficulty walking along with one or several concurrent movement disorders. At the time of anti-IgLON5 diagnosis, 63 (87%) patients had at least one movement disorder with a median of three per patient. The most frequent abnormal movements were gait and balance disturbances (52 patients, 72%), chorea (24, 33%), bradykinesia (20, 28%), dystonia (19, 26%), abnormal body postures or rigidity (18, 25%), and tremor (15, 21%). Other hyperkinetic movements (myoclonus, akathisia, myorhythmia, myokymia, or abdominal dyskinesias) occurred in 26 (36%) patients. The craniofacial region was one of the most frequently affected by multiple concurrent movement disorders (23 patients, 32%) including dystonia (13), myorhythmia (6), chorea (4) or myokymia (4). Considering any body region, the most frequent combination of multiple movement disorders consisted of gait instability or ataxia associated with craniofacial dyskinesias or generalized chorea observed in 31(43%) of patients. In addition to abnormal movements, 87% of patients had sleep alterations, 74% bulbar dysfunction, and 53% cognitive impairment. Fifty-five (76%) patients were treated with immunotherapy, resulting in important and sustained improvement of the movement disorders in only seven (13%) cases.CONCLUSIONS: Movement disorders are a frequent and leading cause of initial neurological consultation in patients with anti-IgLON5 disease. Although multiple types of abnormal movements can occur, the most prevalent are disorders of gait, generalized chorea, and dystonia and other dyskinesias that frequently affect craniofacial muscles. Overall, anti-IgLON5 disease should be considered in patients with multiple movement disorders, particularly if they occur in association with sleep alterations, bulbar dysfunction, or cognitive impairment.
U2 - 10.1212/WNL.0000000000012639
DO - 10.1212/WNL.0000000000012639
M3 - Journal articles
C2 - 34380749
SN - 0028-3878
JO - Neurology
JF - Neurology
ER -